Navigation Links
Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe
Date:7/28/2009

SEATTLE, July 29 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it was notified by the European Medicines Agency ("EMEA") that pixantrone is eligible to be submitted for a Marketing Authorization Application ("MAA") through the EMEA's centralized procedure. The centralized review process provides for a single coordinated review for approval of pharmaceutical products that is conducted by the EMEA on behalf of all European Union ("EU") member states. The EMEA also designated pixantrone as a New Active Substance ("NAS"); if approved, compounds designated as an NAS receive a 10-year market exclusivity period in EU member states. CTI will request a meeting with the EMEA to discuss the submission of the MAA for pixantrone to treat aggressive non-Hodgkin's lymphoma ("NHL") in the EU member states.

CTI completed the submission of the New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for pixantrone to treat relapsed or refractory, aggressive NHL in June 2009 and requested priority review, which if granted could lead to an approval decision from the FDA in the fourth quarter of 2009. Pixantrone is currently available in Europe on a named-patient basis.

"Initiating the approval process for pixantrone in Europe is another significant milestone for CTI," said James A. Bianco, M.D., Chief Executive Officer of CTI. "Additionally, being granted SME status will support and reduce our cost of regulatory filings in Europe. More importantly, it will assist us in our submission of pixantrone for EU approval."

The SME program is an initiative by the EMEA that is dedicated to addressing the needs of small and medium size companies developing medicinal products in Europe. Companies granted SME status are able to seek assistance, information and training from dedicated EMEA personnel, particularly in s
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cell Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Warrants
2. Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement
3. Orexigen(R) Therapeutics Prices Public Offering of Common Stock
4. Cell Therapeutics, Inc. Announces Public Offering of Common Stock and Warrants
5. Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock
6. Oxygen Biotherapeutics, Inc. Announces Closing of Offer to Acquire Warrants
7. Cornerstone Therapeutics David Price Named 2009 Chief Financial Officer of the Year by the Triangle Business Journal
8. Echo Therapeutics to Present at Jessup & Lamont 2009 Growth Stock Conference
9. The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster
10. Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product
11. QuikByte Software, Inc. and Sorrento Therapeutics, Inc. Announce Merger Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... that as many as 10 million older Americans suffer ... and isolation. , However, new research a project ... Americans for six years found that Internet use ... by more than 30 percent. , "That,s a very ... professor of telecommunication, information studies and media who led ...
(Date:4/17/2014)... April 17, 2014 By discovering a new mechanism ... a stroke, researchers at UC Irvine and the Salk ... may limit or prevent stroke-induced brain damage. , A ... cause of death and primary reason for disability in ... a stroke and lets blood-borne material into the brain, ...
(Date:4/17/2014)... Calif.) An international team led by researchers at ... complex, which plays a key role in cell division, ... This is the first time the complex has been ... make cyclin B1/Cdk1 an excellent target to control cellular ... The research was published online today in the journal ...
(Date:4/17/2014)... and their partners have found that their proprietary microbicide ... of multiple sexually transmitted infections (STIs) in both the ... 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded study ... effective against multiple strains of HIV, and has a ... viruses of at least eight hours prior to exposure. ...
Breaking Medicine News(10 mins):Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... The following is a,statement from Matthew L. Myers, ... and Ohio legislators have abandoned Ohio,s kids,and put the ... to,raid funds from the Ohio Tobacco Prevention Foundation. This ... children will become addicted to,tobacco, more Ohio citizens will ...
... April 8, 2008 The Center,for Connected ... of the,nation,s leading integrated health care delivery ... studies conducted at Partners-affiliated,hospitals, including Massachusetts General ... of connected health technologies.,These study findings, presented ...
... to two botanical functional ... ingredients, GLPH-1(TM) and PPL-240(TM), BIG HORN, Wyo., April ... validated and organically derived,ingredients for use in foods and ... GLPH-1(TM), an immune booster, and,PPL-240(TM), a photoprotective antioxidant, at ...
... output, breathing improve, researchers say , , TUESDAY, April 8 ... is enough to boost the cardiac performance and breathing ... finds. , This slightly more strenuous exercise program -- ... failure -- works at least as well as the ...
... What do you learn by looking at the spines of ... of researchers behind the Twin Spine Study, you find compelling ... of genetics than physical strain. , The findings of the ... have led to a dramatic paradigm shift in the way ...
... in the developing world is the litany of tropical ... by the public health community. This is the ... published by ASM Press. , Some of the worst ... ignored. Parasitic and bacterial diseases such as hookworm, ...
Cached Medicine News:Health News:Center for Connected Health Presents Growing Evidence of the Benefits of Technology to Improve Patient Satisfaction and Empowerment 2Health News:Center for Connected Health Presents Growing Evidence of the Benefits of Technology to Improve Patient Satisfaction and Empowerment 3Health News:Center for Connected Health Presents Growing Evidence of the Benefits of Technology to Improve Patient Satisfaction and Empowerment 4Health News:Gourmetceuticals Presents Findings on Science You Can Eat at Experimental Biology 2008 2Health News:Gourmetceuticals Presents Findings on Science You Can Eat at Experimental Biology 2008 3Health News:A Month of Exercise Helps Ease Heart Failure 2Health News:Award-winning study says back pain may be in your genes 2Health News:Forgotten diseases key to lifting developing world from poverty, destitution and despair 2
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Dec. 9, 2010 Customers using Elekta,s ... with seamless integration to Varian,s TrueBeam ™ ... to this linear accelerator is the most recent ... and the delivery systems of other cancer management ...
... Conn., Dec. 9, 2010 Boehringer Ingelheim Pharmaceuticals, Inc. ... the phase IIb/III LUX-Lung 1 trial show that afatinib ... 1.0 month for placebo) in progression-free survival (PFS) in ... to have an epidermal growth factor receptor (EGFR) mutation.(1) ...
Cached Medicine Technology:Cancer Treatment Centers' Oncology Information System Options Expand with New MOSAIQ Connectivity 2Cancer Treatment Centers' Oncology Information System Options Expand with New MOSAIQ Connectivity 3New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations 2New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations 3New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations 4New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations 5
For the qualitative detection of human Chorionic Gonadotrophin (hCG) in urine specimens...
For the qualitative detection of human Chorionic Gonadotrophin (HCG) in urine or urine and serum specimens...
ZyDoc offers a full medical transcription and documentation solution....
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: